Latest Series A Funding Rounds
Companies raising their first major institutional growth round, from the product they sell to the investors backing their next stage.
- Rounds
- 865 All time
- Disclosed funding
- $32.5B 782 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| RS Provides automated threat exposure remediation platform | $20M | Series A | Cybersecurity | United States | Investors | |
| S ShellworksCompany profile Develops bio-based plastic alternative materials for packaging and consumer goods Develops bio-based plastic alternative materials for packaging and consumer goods | $15M | Series A | Climate tech | United Kingdom | Investors | |
| P PhotoncycleCompany profile Builds solid-state hydrogen systems for households to store summer solar power for winter use Builds solid-state hydrogen systems for households to store summer solar power for winter use | €15M | Series A | Climate tech | Norway | Investors | |
| A ArtemisCompany profile Provides AI-powered design sales financing and compliance automation for distributed energy Provides AI-powered design sales financing and compliance automation for distributed energy | $6M | Series A | Climate tech | United States | Investors | |
| XS Xsensio SACompany profile Develops wearable biosensing platform for continuous biochemical monitoring Develops wearable biosensing platform for continuous biochemical monitoring | $7M | Series A | Healthtech | Switzerland | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $45M | Series A+Series A | Biotech | United States | Investors | |
| A AntiverseCompany profile Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. | $9.3M | Series A | Healthtech | United Kingdom | Investors | |
| ST Smack TechnologiesCompany profile Frontier AI lab building domain-specific decision-making models for the military Frontier AI lab building domain-specific decision-making models for the military | $32M | Series A | Defense tech | United States | Investors | |
| D Provides AI solutions to turn enterprise AI pilots into real business results | Undisclosed | Series A | AI | Singapore | Investors | |
| EH Provides AI-native operating system for behavioral health providers | $41M | Series A | Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Y Combinator (YC)
Clueso, Santé, Flai
52rounds0led - 2Andreessen Horowitz (a16z)
Eka Robotics, TypeSafe AI, Sharp Performance
29rounds9led - 3General Catalyst
Baba, Melius, Disha (formerly Curelink)
24rounds1led - 4Lightspeed
Warp Sciences, Zenzap, Avarra
21rounds4led - 5Alumni Ventures
Chariot Claims, RegCell, Inc., Lightfield
21rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.